Komori
Mitsubishi Chemical Group (4188) · RiskMitigatedLatest General Meetings of Shareholders (2026-05-26): "Advanced"

Pharmaceutical business risks related to drug price revisions, new drug development, competition and adverse reactions

First written in FY2016. 12 of 24 entries say "Materialised", first in FY2017-Q2. Latest entry: 2026-05-26.

24entries
11years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseMaterialisedFY2017-Q2 – FY2020-Q1MaterialisedFY2022-Q1MitigatedFY2025-H1 – 2026-05-262016: 220162017: 120172018: 320182019: 420192020: 420202021: 320212022: 020222023: 420232024: 220242025: 020252026: 12026
Same theme, other companies

Mitsubishi Chemical Group moved to the "Worse" side of this theme in 2016, 4 years before the typical company in this theme (2020).

The whole theme swung hardest in 2020: 31 of 70 companies on the "Worse" side.

1 other company's latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 101 companies compared. The sentences above are computed from all 101.
Full recordFilings, disclosures and news, newest first
  1. 2026-05-26AdvancedGeneral Meetings of Shareholders

    「The Group conducts centralized risk management activities based on the rules relating to enterprise risk management (ERM).」

    For enterprise risk management, the disclosure described centralized activities based on ERM-related rules and the operation of selecting and monitoring material risks through the ERM Committee.
  2. FY2025-H1MitigatedAnnual report

    「In pharmaceuticals, both revenue and core operating profit increased despite the impact of drug price revisions and other factors on domestic prescription drugs, due to growth in RADICAVA ORS®, a treatment for amyotrophic lateral sclerosis (ALS) launched in the United States, and foreign exchange effects; growth in Mounjaro, a long-acting GIP/GLP-1 receptor agonist, and influenza vaccines; and the smooth launch of Govic® aqueous suspension for injection, a combined adsorbed, purified pertussis, diphtheria, tetanus, inactivated polio and Haemophilus influenzae type b vaccine.」

    Although the impact of drug price revisions and other factors remains, Pharmaceuticals revenue and core operating profit increased on growth in sales of RADICAVA ORS, Mounjaro, influenza vaccines and Govy.
  3. FY2024-Q3RestatedAnnual report

    「Revenue increased despite the impact of drug price revisions and other factors on domestic prescription drugs, due to steady sales of key products, new products and RADICAVA ORS®, a treatment for amyotrophic lateral sclerosis (ALS) launched in the United States.」

    Although the impact of drug price revisions and other factors remains, the company has reconfirmed that Healthcare revenue increased as sales of priority products, new products and RADICAVA ORS remained on a steady track.
  4. FY2024-Q2RestatedAnnual report

    「Revenue increased despite the impact of drug price revisions and other factors on domestic prescription drugs, due to steady sales of key products and RADICAVA ORS®, a treatment for amyotrophic lateral sclerosis (ALS) launched in the United States.」

    Although the impact of drug price revisions and other factors remains, the company has reconfirmed that pharmaceutical revenue increased as sales of priority products and RADICAVA ORS remained on a steady track.
  5. FY2024-Q1MitigatedAnnual report

    「Revenue increased despite the impact of drug price revisions and other factors on domestic prescription drugs, due to steady sales of key products and RADICAVA ORS®, a treatment for amyotrophic lateral sclerosis (ALS) launched in the United States.」

    Although the impact of drug price revisions and other factors continued, Healthcare revenue and core operating profit increased year on year on growth in sales of priority products and RADICAVA ORS in the United States.
  6. FY2023MitigatedAnnual report

    「In pharmaceuticals, both revenue and core operating profit increased despite the impact of drug price revisions and other factors on domestic prescription drugs, due in part to steady sales of key products and RADICAVA ORS®, a treatment for amyotrophic lateral sclerosis (ALS) launched in the United States.」

    Although risks from drug price revisions and other factors remain, pharmaceutical revenue and core operating profit increased on growth in sales of priority products and RADICAVA ORS.
  7. FY2023-Q3MitigatedAnnual report

    「In pharmaceuticals, both revenue and core operating profit increased despite the impact of drug price revisions and other factors on domestic prescription drugs, due in part to steady sales of key products and RADICAVA ORS®, a treatment for amyotrophic lateral sclerosis (ALS) launched in the United States.」

    Although the impact of drug price revisions and other factors continued, pharmaceutical revenue and core operating profit increased on growth in sales of priority products and RADICAVA ORS.
  8. FY2022-Q1MaterialisedAnnual report

    「In pharmaceuticals, revenue increased despite the impact of drug price revisions and other factors on domestic prescription drugs, due in part to higher sales volumes of key products. Core operating profit decreased, mainly due to higher research and development expenses for COVID-19 vaccines.」

    The impact of drug price revisions and other factors, together with higher vaccine R&D expenses, was reflected in a decline in core operating profit in the Pharmaceuticals business in the first quarter.
  9. FY2021RestatedAnnual report

    「In general, research and development of new drugs takes longer than in other industries, and the probability of obtaining approval is not high. It is therefore difficult to accurately predict the likelihood and timing of commercialization, and failure to commercialize a new drug as planned could affect performance.」

    The company continues to cite risks to the pharmaceutical business related to new drug development and approval, competition, drug price revisions and adverse reactions.
  10. FY2021-Q3RestatedAnnual report

    「In pharmaceuticals, revenue declined due to lower domestic prescription pharmaceutical sales resulting from the drug price revision and other factors. However, core operating profit was at about the same level as in the same period of the previous year because selling expenses and research and development expenses decreased as activities were curtailed in response to the spread of COVID-19.」

    While lower domestic prescription pharmaceutical revenue due to the drug price revision and other factors continued, the Healthcare segment's core operating profit remained at about the same level as in the same period of the previous year because selling expenses and research and development expenses declined as activities were curtailed.
  11. FY2021-Q2MaterialisedAnnual report

    「As the profitability of the Parkinson’s disease treatment being developed by NeuroDerm was expected to decline due to changes in the business environment, the plan was reviewed based on market research. Because the recoverable amount fell below the carrying amount, the carrying amount of the intangible asset related to the technology, consisting of in-process research and development costs, was reduced to its recoverable amount of ¥43,272 million.」

    Risks related to new drug development, approval and profitability actually materialized as an ¥84.534 billion impairment loss on in-process research and development related to NeurolDerm's Parkinson's disease treatment.
  12. FY2021-Q1MaterialisedAnnual report

    「In pharmaceuticals, revenue declined due to lower domestic prescription pharmaceutical sales resulting from the drug price revision and other factors. However, core operating profit was at about the same level as in the same period of the previous year because selling expenses and research and development expenses decreased as activities were curtailed in response to the spread of COVID-19.」

    The decline in domestic prescription pharmaceutical sales caused by the drug price revision and other factors actually emerged as a decrease in pharmaceutical revenue in the first quarter.
  13. FY2020MaterialisedAnnual report

    「The Group decided not to seek US approval for MT-2271, a plant-derived VLP vaccine intended to prevent seasonal influenza. Accordingly, ¥24.1 billion in intangible assets related to MT-2271 (in-process research and development costs) was recognized as an impairment loss, a non-recurring item, in the financial results for the fiscal year ended March 2020.」

    Uncertainty over the development and approval of new drugs and vaccines actually materialized as the decision not to submit an application for US approval of MT-2271 and a ¥24.1 billion impairment loss on intangible assets.
  14. FY2020-Q3RestatedAnnual report

    「In pharmaceuticals, domestic prescription pharmaceutical sales increased, mainly for key products, but both revenue and core operating profit declined due to lower royalty income and other factors. With respect to royalty income from Gilenya, a multiple sclerosis treatment licensed to Novartis Pharma AG (Switzerland), arbitration proceedings began in February 2019, and revenue has not been recognized for part of the royalty income in accordance with IFRS 15. As the arbitration proceedings remained ongoing during the nine months ended in the third quarter, the income was not recognized as revenue, resulting in lower revenue.」

    The arbitration proceedings over Gilenya royalties and the non-recognition of part of the royalty income as revenue have continued.
  15. FY2020-Q2RestatedAnnual report

    「In pharmaceuticals, domestic prescription pharmaceutical sales increased, mainly for key products, but both revenue and core operating profit declined due to lower royalty income and other factors. With respect to royalty income from Gilenya, a multiple sclerosis treatment licensed to Novartis Pharma AG (Switzerland), arbitration proceedings began in February 2019, and revenue has not been recognized for part of the royalty income in accordance with IFRS 15. As the arbitration proceedings remained ongoing during the six months ended in the second quarter, the income was not recognized as revenue, resulting in lower revenue.」

    The company reconfirms that arbitration over Gilenya royalties remains ongoing, part of the royalty income is not being recognized as revenue, and the pharmaceutical business has experienced lower revenue and profit.
  16. FY2020-Q1MaterialisedAnnual report

    「Revenue in the segment was ¥107.9 billion, down ¥7.5 billion year on year, and core operating profit was ¥9.3 billion, down ¥10.3 billion. In pharmaceuticals, domestic prescription pharmaceutical sales increased, mainly for key products, but both revenue and core operating profit declined due to lower royalty income and other factors.」

    The company states that lower royalty income and other factors caused declines in Healthcare segment revenue and core operating profit.
  17. FY2019MaterialisedAnnual report

    「In pharmaceuticals, sales of Radicava, a treatment for amyotrophic lateral sclerosis (ALS), grew in the US, but revenue declined in domestic prescription pharmaceuticals due to the drug price revision implemented in April 2018, lower royalty income and other factors. Core operating profit declined due to the impact of lower revenue, as well as higher research and development expenses and other factors.」

    The drug price revision, lower royalty income and higher research and development expenses emerged over the full year as lower revenue and profit in the Healthcare segment.
  18. FY2019-Q3MaterialisedAnnual report

    「In pharmaceuticals, sales revenue and core operating profit both declined due to the April 2018 drug price revision, the October 2017 transfer of the generic drug business, and other factors affecting domestic prescription drugs, despite growth in US sales of Radicava, a treatment for amyotrophic lateral sclerosis (ALS).」

    The drug price revision and the transfer of the generic drug business and other factors continued to emerge as declines in Healthcare segment revenue and core operating profit despite growth in US sales of Radicava.
  19. FY2019-Q2MaterialisedAnnual report

    「Revenue in the segment was ¥269.5 billion, down ¥3.7 billion year on year, and core operating profit was ¥35.3 billion, down ¥5.7 billion. In pharmaceuticals, sales of Radicava, a treatment for amyotrophic lateral sclerosis (ALS), grew in the US, but both revenue and core operating profit declined due to the drug price revision implemented in April 2018, the transfer of the generic drug business in October 2017 and other factors affecting domestic prescription pharmaceuticals.」

    The drug price revision, the transfer of the generic drug business and other factors emerged during the six months ended in the second quarter as lower revenue and profit in the Healthcare segment.
  20. FY2019-Q1MaterialisedAnnual report

    「Revenue in the segment was ¥135.6 billion, down ¥2.5 billion year on year, and core operating profit was ¥20.1 billion, down ¥1.9 billion. In pharmaceuticals, sales of Radicava, a treatment for amyotrophic lateral sclerosis (ALS), grew in the US, but revenue declined because domestic prescription pharmaceuticals reported lower sales following the drug price revision implemented in April 2018 and the transfer of the generic drug business in October 2017. In addition to the above, core operating profit declined due to higher research and development expenses in pharmaceuticals.」

    The drug price revision and higher research and development expenses emerged in the first quarter as lower revenue and profit in the Healthcare segment, including the pharmaceutical business.
  21. FY2018MaterialisedAnnual report

    「Core operating profit declined due to higher research and development expenses and costs associated with expanding the business in the US pharmaceutical market.」

    The company states that expansion in the US and higher research and development expenses reduced the Healthcare segment's core operating profit by ¥17.2 billion year on year.
  22. FY2017-Q3MaterialisedAnnual report

    「Core operating profit declined due to the impact of the drug price revision and other factors, despite higher pharmaceutical revenue.」

    The impact of the drug price revision continued to emerge as a decline in the Healthcare segment's core operating profit despite higher pharmaceutical revenue.
  23. FY2017-Q2MaterialisedAnnual report

    「Core operating profit declined due to the impact of the drug price revision and other factors, despite higher pharmaceutical revenue.」

    The Healthcare segment's core operating profit declined ¥3.0 billion year on year due to the impact of the drug price revision in April 2016. Firm sales were also noted.
  24. FY2016First statedAnnual report

    「In general, research and development of new drugs takes longer than in other industries, and the probability of obtaining approval is not high. It is therefore difficult to accurately predict the likelihood and timing of commercialization, and failure to commercialize a new drug as planned could affect performance.」

    The company describes reductions in drug prices, uncertainty over the development and approval of new drugs, competition, adverse reactions and patent expirations as risks to the pharmaceutical business.
Moved together

"Deteriorating profitability and impairment at petrochemical and materials facilities" moved the same way as this thread, in the same document, in 11 of its 24 moves.

11109443★123456
  1. ★This thread
  2. 1Deteriorating profitability and impairment at petrochemical and materials facilities11×
  3. 2Earnings volatility arising from demand, market conditions, raw material prices, foreign exchange and supply constraints10×
  4. 3Funding risks from interest-bearing debt, interest rates and credit-rating downgrades9×
  5. 4Improving profitability through cost reductions and asset reduction4×
  6. 5Circular Economy and Climate Change Measures Looking Toward 2050 and 20304×
  7. 6Portfolio and Structural Reform of the Petrochemicals Business3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Mitsubishi Chemical Group yet. It last moved in the General Meetings of Shareholders of 2026-05-26: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.